Inside ICH: ICH Implementation Support - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside ICH: ICH Implementation Support
ICH Q8, Q9, and Q10 support and implications for the future.


Pharmaceutical Technology
Volume 36, Issue 2, pp. 52-53

The mission of the International Conference on Harmonization (ICH) is to make recommendations towards achieving greater harmonization in the interpretation and application of technical guidelines and requirements for pharmaceutical product registration. The organization, launched in 1990, brings together the drug regulatory authorities and the pharmaceutical industry associations of Europe, Japan, and the United States.

Regulatory harmonization offers many direct benefits to both regulatory authorities and the pharmaceutical industry with beneficial impact for the protection of public health. Key benefits include: streamlining the regulatory assessment process for new drug applications, and reducing the development times and resources for drug development.

Harmonization is achieved through the development of ICH Tripartite Guidelines, which are developed through a process of scientific consensus among regulators and industry. Key to the success of this process, however, is the commitment of the ICH regulators, including FDA, EMA, and Japan's Ministry of Health, Labor & Welfare, to implement the final guidelines.

The new ICH paradigm

In 2003, the quality experts in ICH developed a new vision: "Develop a harmonized pharmaceutical quality system applicable across the lifecycle of the product emphasizing an integrated approach to quality risk management and science" (1). This goal led to the creation of the following Quality guidelines: ICH Q8 Pharmaceutical Development; ICH Q9 Quality Risk Management; ICH Q10 Pharmaceutical Quality System, and the pending ICH Q11 Development and Manufacturing of Drug Substance (see cover story in this issue for details).

These guidelines represented methodologies addressing the challenges of the pharmaceutical industry with regard to emerging techniques based on the rapid growth of technology and new opportunities in drug development and manufacturing. These guidelines introduced in detail a new quality vision for industry, one focused on science- and risk-based concepts and approaches, and one that emphasized an adequate quality system. In addition, ICH Q9 was the first harmonized document applicable to processes performed by both industry and regulators.

Following these developments, the ICH Quality Implementation Working group (Q–IWG) worked out a way to facilitate harmonized implementation of this new paradigm. The Q8, Q9, and Q10 guidelines, although independent, are interlinked. As a consequence, implementation support was needed and provided.

Implementation support

The ICH Steering Committee endorsed the establishment of the Q–IWG to ensure the globally consistent implementation of ICH Q8, Q9, and Q10, and to make sure that maximum benefit is achieved from the interaction between these guidelines (1). In parallel, Q–IWG supported the development of ICH Q11 to guarantee a harmonized approach. As its first deliverable, Q–IWG developed a Question-and-Answer document (Q&A) about the guidelines as well as enhanced training (2).

Q&As. The Q&A document answers key questions raised at several conferences and workshops. For example, clarification of process validation and continuous process verification are included, as are answers related to questions about quality by design (QbD), including design space, real-time release testing (RTRT), and control strategy. The series of answers about the pharmaceutical quality system focus on inspection practices, knowledge management, and software solutions (2).

Training program. Defining how the ICH Quality guidelines work together throughout the product lifecycle was a key goal of the Q–IWG training and workshop series, held from 2009 to 2011, in Tallinn; Washington, DC; Ottawa; and Seoul, with participation from the ICH Global Cooperation Group and the Asia–Pacific Economic Community. A case study was developed for the training workshops to explain how a product developed using a science- and risk-based approach might be challenged during regulatory assessment. Postapproval manufacturing implementation, quality system considerations, and potential thoughts during inspections were included in the case-study discussion.

In addition, key messages on design space, control strategy, pharmaceutical quality systems, and quality risk management were discussed through interactive sessions among participants and Q–IWG members. Slides of the presentations are available in English and Japanese (3). During these training workshops, participants brought up many additional questions not addressed in the Q&A document, which triggered the need for further clarifications.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here